Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Eli Lilly (NY:LLY)

779.28 UNCHANGED
Streaming Delayed Price Updated: 7:00 PM EDT, Jul 2, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Eli Lilly

< Previous 1 2 3 4 5 6 7 8 9
...
99 100 Next >
9 Health Care Stocks With Whale Alerts In Today's Session
Via Benzinga
3 Stocks That Will Profit From Trump's Drug Price Cut
Trump's EO aims to lower US drug prices by using leverage of public programs (like Medicare) to force accountability. Big pharma may be hit hardest. 
Via Benzinga
Topics Government
Stocks Fight For Fifth Day Of Gains, Dollar Rebounds As Inflation Fears Go Haywire: What's Driving Markets Friday?
Wall Street fought for a fifth consecutive day of gains on Friday, with major indexes edging slightly higher by midday in New York as investors continued to digest the week's significant trade... 
Via Benzinga
Topics Economy
Explore the top gainers and losers within the S&P500 index in today's session.
Let's have a look at the top S&P500 gainers and losers in the middle of the day of today's session. 
Via Chartmill
Novo Nordisk Sheds 4% After Ousting CEO As Eli Lilly Rivalry Slams Stock Price
Novo Nordisk said Friday it will replace its CEO, citing a sharp tumble for Novo shares amid growing competition. 
Via Investor's Business Daily
Wall Street Expects This Obesity Drug Stock to Skyrocket 35% Over the Next 12 Months
Via The Motley Fool
Eli Lilly Collaborates With Rznomics On Hearing Loss Treatment In $1.3 Billion Pact
Eli Lilly signs a global licensing deal with Rznomics to co-develop RNA-editing therapies for hearing loss, with potential deal value above $1.3 billion. 
Via Benzinga
Is It Time to Buy the Dip in Novo Nordisk Stock?
Novo Nordisk stock is down nearly 50% in 2025 as competition in the GLP-1 space continues to mount, but the fundamental case for the NVO stock is growing 
Via MarketBeat
Topics Government
What Most-Favored-Nation Status Could Mean for Pharmaceutical Stocks
Via The Motley Fool
Topics Economy Government
2 Stocks That Plummeted During President Trump's First 100 Days in Office, and Where They Could Be Headed
The stock market experienced quite a bit of volatility during President Donald Trump's first 100 days in office. 
Via The Motley Fool
Topics Artificial Intelligence Fraud Government
3 Market-Beating Stocks with Promising Prospects
The best-performing stocks typically have robust sales growth, increasing margins, and rising returns on capital, and those that can maintain this trifecta year in and year out often become the legends... 
Via StockStory
LLY Q1 Earnings Call: Revenue Beats Expectations, Profit Guidance Trimmed Amid Price Pressures
Global pharmaceutical company Eli Lilly (NYSE:LLY) reported revenue ahead of Wall Street’s expectations in Q1 CY2025, with sales up 45.2% year on year to $12.73 billion. The company expects the full... 
Via StockStory
Sanofi To Navigate Tariff Impact With $20 Billion In Spending Through 2030
Sanofi plans $20 billion US investment by 2030 to expand R&D and manufacturing, aiming to boost medicine production and job creation across states. 
Via Benzinga
Unpacking the Latest Options Trading Trends in Eli Lilly
Via Benzinga
Got $500? 1 Billionaire-Approved Vanguard Index Fund to Buy and Hold Forever
Investing in index funds can be an incredibly lucrative way to build wealth. 
Via The Motley Fool
Topics ETFs Economy
Why Weight-Loss Developer Stocks Tumbled on Tuesday
Via The Motley Fool
Topics Government
2 Monster Stocks in the Making to Buy Now and Hold for 10 Years
Via The Motley Fool
Market Monitor News May 12 ( NRG Energy, Amazon, Meta Platforms UP - CVS Health DOWN)
Wall Street surges sharply as US-China tariff cuts drive tech stocks higher; pharma sector gains on new Trump drug pricing initiative. 
Via Chartmill
Topics Government World Trade
Eli Lilly (LLY): Buy, Sell, or Hold Post Q1 Earnings?
Eli Lilly trades at $759 per share and has stayed right on track with the overall market, losing 6.5% over the last six months while the S&P 500 is down 2.4%. This was partly driven by its softer... 
Via StockStory
Topics Government Stocks
Let's take a look at the S&P500 stocks that are experiencing unusual volume in today's session.
Discover the S&P500 stocks that are experiencing unusual trading volume in today's session. Find out more about these stocks below. 
Via Chartmill
Ford’s Cologne Workers To Strike On Wednesday, Says Report: Retail Sentiment Sours
According to a Reuters report, the strike comes in the wake of planned job cuts in the region. 
Via Stocktwits
Topics Government
KindlyMD Stock Surges To All-Time High After Announcing Merger With Nakamoto To Launch Bitcoin Treasury Strategy
KindlyMD CEO Tim Pickett said the merger allows the company to preserve and expand its mission to combat opioid dependency through alternative medicine while gaining a new engine for shareholder value... 
Via Stocktwits
Topics Government Regulatory Compliance
Big News! U.S. and China Trade Deal Shakes Up Markets
Stocks are soaring today on the hope that the trade tensions between the U.S. and China are behind us. 
Via The Motley Fool
Topics World Trade
Merck, Pfizer, Eli Lilly Stocks Rebound As Trump Targets Drug Costs With New Executive Order
The U.S. President said that Big Pharma would either voluntarily abide by this principle or the federal government will use its power to ensure the U.S. pays the same price as other countries. 
Via Stocktwits
Topics Government
Top S&P500 movers in Monday's pre-market session
Stay updated with the S&P500 stocks that are on the move in today's pre-market session. 
Via Chartmill
Wall Street Rips Higher As Tariff Truce Halts US–China Economic Escalation
US-China agree to slash tariffs by over 100%, easing fears of economic slowdown and inflation. Markets cheer with futures rising and yields up. 
Via Benzinga
Topics Economy World Trade
Mark Cuban Slams Charlie Kirk Over Drug Price Debate, Says PBMs — Not Big Pharma — Are The Real Villains: 'For Your Company...Ask Your PBM For A List Of Claims'
Mark Cuban, the billionaire entrepreneur, challenged Trump-supporter and political activist Charlie Kirk's stance on high drug prices, asserting that Pharmacy Benefit Managers (PBMs) are the main... 
Via Benzinga
Billionaire Chase Coleman Has 68% of His $24.5 Billion Portfolio Invested in 10 Stocks. Here's the Best of the Bunch.
Via The Motley Fool
Topics Artificial Intelligence
Eli Lilly's Zepbound Shows Superior Weight Loss Over Novo Nordisk's Wegovy In Head-To-Head Trial
Eli Lilly and Company's Zepbound demonstrated superior weight reduction compared to Novo Nordisk's Wegovy in a 72-week head-to-head trial. 
Via Benzinga
3 Healthcare Stocks to Keep an Eye On
Personal health and wellness is one of the many secular tailwinds for healthcare companies. But financial performance has lagged recently as players offloaded surplus COVID inventories in 2023 and... 
Via StockStory
Topics Stocks
< Previous 1 2 3 4 5 6 7 8 9
...
99 100 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.